Source: Business Wire

Press Release: Glaukos : Glaukos iStent inject® Implantation with Concomitant Cataract Surgery Provides Sustained Reduction in IOP and Medication Burden, According to New Study

SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies designed to transform the treatment of glaucoma, announced today that a single-site international study of glaucoma subjects recently published in Ophthalmology and Therapy showed that the iStent inject® Trabecular Micro-Bypass System, combined with ca

Read full article »

Top Competitors or Alternatives

Missing a competitor? Contribute!

Annual Revenue
Employees
Thomas W Burns's photo - President & CEO of Glaukos

President & CEO

Thomas W Burns

CEO Approval Rating

88/100

Glaukos is an ophthalmic medical device firm that creates micro invasive glaucoma surgery options for patients. Read more